Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bromazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 known ✓ | P47869 | 8/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 8/20 | 0.65 |
| ▸ | GABRA5 | P31644 | 8/20 | 0.65 |
| ▸ | GABRA3 | P34903 | 8/20 | 0.65 |
| ▸ | GABRB2 | P47870 | 7/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.60 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | GABRP | O00591 | 3/20 | 0.48 |
| ▸ | GABRD | O14764 | 3/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.48 |
| ▸ | GABRE | P78334 | 3/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromazepam SCHEMBL29366892 | 1.00 | ADRA1A (1.00) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| Bromazepam SCHEMBL29382152 | 1.00 | ADRA1A (1.00) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| Bromazepam SCHEMBL29521776 | 1.00 | ADRA1A (1.00) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| Bromazepam SCHEMBL17225092 | 0.85 | ADRA1A (0.73) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| Bromazepam SCHEMBL8414304 | 0.85 | ADRA1A (0.73) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL7377690 | 0.85 | ADRA1A (0.74) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL7374778 | 0.85 | ADRA1A (0.74) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL7951942 | 0.85 | ADRA1A (0.74) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL14215423 | 0.85 | ADRA1A (0.74) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL7477766 | 0.84 | ADRA1A (0.72) | ADRA1AGABRA1GABRA5GABRA3GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9150 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-20260115161-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | LAMINAR PHARMACEUTICALS S A (ES) | 2026-04-30 | — | — | US | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4663187-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | Laminar Pharmaceuticals, S.A. (ES) | 2025-12-17 | — | — | EP | claimed |
| US-20250375421-A1 | METHODS OF USING DMT | SHULMAN WILLIAM (US) | 2025-12-11 | — | — | US | claimed |
| EP-4633614-A1 | STABLE PHARMACEUTICAL COMPOSITION OF AN AMINE DRUG | Sun Pharmaceutical Industries Limited (IN) | 2025-10-22 | — | — | EP | claimed |
| US-12396981-B2 | Methods of using DMT | SHULMAN WILLIAM (US) | 2025-08-26 | — | — | US | claimed |
| US-12350379-B2 | Extended release pharmaceutical formulation and methods of treatment | DOUGLAS PHARMACETICALS LTD (NZ) | 2025-07-08 | — | — | US | claimed |
| US-20250179064-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICALS LLC | 2025-06-05 | — | — | US | claimed |
| EP-0216555-A2 | Use of dioxopiperidine derivatives in the treatment of anxiety, for the reduction of chronic abnormally high brain levels of serotonin or 5-hydroxy-indoleacetic acid, and in the treatment of bacterial or viral infections | BTG INTERNATIONAL LIMITED (GB) | 1987-04-01 | — | — | EP | claimed |
| US-4595684-A | Method of suppressing benzodiazepine induced sedation with 2-(p-methoxypenyl)-pyrazolo[4,3-c]quinolin-3(5H)-one or a salt thereof | CIBA-GEIGY CORPORATION (US) | 1986-06-17 | — | — | US | claimed |
| US-4557934-A | ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE | THE PROCTER & GAMBLE COMPANY (US) | 1985-12-10 | — | — | US | claimed |
| EP-0150721-A2 | Drug | Firma Paliz, Ziegler (CH) | 1985-08-07 | — | — | EP | claimed |
| EP-0110955-A1 | BRAIN-SPECIFIC DRUG DELIVERY. | UNIV FLORIDA (US) | 1984-06-20 | — | — | EP | claimed |
| WO-1983003968-A1 | BRAIN-SPECIFIC DRUG DELIVERY | UNIVERSITY OF FLORIDA (US) | 1983-11-24 | — | — | WO | claimed |
| EP-0050487-A1 | Pharmaceutical compositions comprising a benzodiazepine drug and a phenanthridine derivative | PFIZER INC. (US) | 1982-04-28 | — | — | EP | claimed |
| US-4316897-A | TRANQUILIZERS | HOFFMANN-LA ROCHE INC. (US) | 1982-02-23 | — | — | US | claimed |
| EP-0025546-A2 | Therapeutical use of tranquillizing benzodiazepine derivatives and mixtures containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-03-25 | — | — | EP | claimed |
| US-4028467-A | Analgesic compositions comprising levo-propoxyphene and benzo diazepine and process | BERGER FRANK M | 1977-06-07 | — | — | US | claimed |